| Dr Jessica Baldetti, DO | |
|
226 S Woods Mill Rd Ste 68w, Chesterfield, MO 63017-3665 | |
| (314) 205-6788 | |
| (314) 590-5954 |
| Full Name | Dr Jessica Baldetti |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 226 S Woods Mill Rd Ste 68w, Chesterfield, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134508864 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 125066850 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West County Women's Healthcare, Llc | 2961534417 | 7 |
News Archive
Researchers from the Institute of Neurosciences of the UB and from IDIBAPS together with a team from the University Pierre and Marie Curie and the Institute du Fer à Moulin, published a study in Nature Communications, which demonstrates that the regulation in Pyk2, a protein-tyrosine kinase, causes alterations of the synaptic plasticity involved in memory tasks, associated with the hippocampus in mouse models of neurodegenerative diseases, such as Huntington's.
A new guideline issued by the American Academy of Neurology recommends doctors use caution when choosing seizure drugs for people with HIV/AIDS to avoid potential drug interactions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.
Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.
ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.
› Verified 7 days ago
| Entity Name | West County Women's Healthcare, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447570395 PECOS PAC ID: 2961534417 Enrollment ID: O20100719000438 |
News Archive
Researchers from the Institute of Neurosciences of the UB and from IDIBAPS together with a team from the University Pierre and Marie Curie and the Institute du Fer à Moulin, published a study in Nature Communications, which demonstrates that the regulation in Pyk2, a protein-tyrosine kinase, causes alterations of the synaptic plasticity involved in memory tasks, associated with the hippocampus in mouse models of neurodegenerative diseases, such as Huntington's.
A new guideline issued by the American Academy of Neurology recommends doctors use caution when choosing seizure drugs for people with HIV/AIDS to avoid potential drug interactions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.
Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.
ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica Baldetti, DO 7435 W Talcott Ave, Resurrection Ob/gyn Residency, Chicago, IL 60631-3707 Ph: () - | Dr Jessica Baldetti, DO 226 S Woods Mill Rd Ste 68w, Chesterfield, MO 63017-3665 Ph: (314) 205-6788 |
News Archive
Researchers from the Institute of Neurosciences of the UB and from IDIBAPS together with a team from the University Pierre and Marie Curie and the Institute du Fer à Moulin, published a study in Nature Communications, which demonstrates that the regulation in Pyk2, a protein-tyrosine kinase, causes alterations of the synaptic plasticity involved in memory tasks, associated with the hippocampus in mouse models of neurodegenerative diseases, such as Huntington's.
A new guideline issued by the American Academy of Neurology recommends doctors use caution when choosing seizure drugs for people with HIV/AIDS to avoid potential drug interactions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.
Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.
ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.
› Verified 7 days ago
Dr. Caroline Anne Morgan, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 226 S Woods Mill Rd, Suite 68 West, Chesterfield, MO 63017 Phone: 314-576-0930 Fax: 314-514-8229 | |
Dr. Stephen C Yim, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 226 S Woods Mill Rd, Suite 55 West, Chesterfield, MO 63017 Phone: 314-469-4440 Fax: 314-576-2346 | |
Dr. Laura Irene Moore, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 224 South Woods Mill Road, Suite 750, Chesterfield, MO 63017 Phone: 314-576-9797 Fax: 314-469-7517 | |
Dr. Joe Edward Belew, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 224 S Woods Mill Rd, Suite 750, Chesterfield, MO 63017 Phone: 314-576-9797 Fax: 314-469-7517 | |
Katherine A Maxson, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 226 S Woods Mill Rd, S5w, Chesterfield, MO 63017 Phone: 314-469-0001 | |
Marta I Pineda, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 226 S Woods Mill Rd, Ste 61w, Chesterfield, MO 63017 Phone: 314-205-6957 |